Curative effect and safety of the new generation of anti-vascular endothelial growth factor drugs in neovascular eye diseases
10.3760/cma.j.issn.2095-0160.2014.10.016
- VernacularTitle:眼科新一代抗血管内皮生长因子药物的基础研究及临床试验进展
- Author:
Chunyan, LEI
- Publication Type:Journal Article
- Keywords:
Vascular endothelial growth factor;
Age-related macular degeneration/treatment;
Retina;
Choroidal neovascularization/treatment;
Drug
- From:
Chinese Journal of Experimental Ophthalmology
2014;32(10):938-942
- CountryChina
- Language:Chinese
-
Abstract:
Retinal neovascularization,a common pathological process of a variety of eye diseases,is a major cause of blindness.Vascular endothelial growth factor (VEGF) has been believed to be the most important therapeutic target of neovascular eye diseases.In the era of anti-VEGF for retinal diseases,several drugs aiming at the single molecular target VEGF-A have achieved considerable success in decreasing neovascularization and relieving the symptoms.In the past two years,novel anti-VEGF drugs aiming at multiple molecular targets including VEGF-A,VEGF-B and PlGF have surged into clinic service.Represented by aflibercept (VEGF Trap-Eye,Eylea) and conbercept (KH902),multiple targets anti-VEGF drugs relieve the clinical symptoms in patients resistant to single target anti-VEGF drugs.In addition,because similar curative effects are achieved with longer injection interval,risk of complications related to the intraocular injection procedure is reduced.However,it is reported that the additional inhibited targets are associated with maintaining the normal functions of blood vessels and neurons.Therefore,although there are still no severe adverse effects for these new developed drugs,further long-term observation is mandatory to evaluate their safety.In this review,we summarized the characteristics of aflibercept and conbercept,a new generation of anti-VEGF drugs,from the aspects of basic research,pharmacokinetics,efficacy,safety and the existing problems.
